New data could revive Pfizer's Mylotarg
This article was originally published in Scrip
Executive Summary
New investigator-initiated research could help revive Pfizer's acute myeloid leukaemia (AML) treatment, Mylotarg (gemtuzumab ozogamicin), following the withdrawal of the product last year.